Photo of Natasha K. Stout,

Natasha K. Stout

Harvard Medical School

Harvard Medical School
Phone: (617) 867-4914
Fax: (617) 867-4276


natasha_stout@hms.harvard.edu

Natasha K. Stout

Harvard Medical School

EDUCATIONAL TITLES

  • Assistant Professor, Population Medicine, Harvard Medical School

DF/HCC PROGRAM AFFILIATION

Research Abstract

My research experiences and interests center on the development and utilization of population-based computer simulation models of the natural history of cancer to inform decision making in health policy and improve population health. Specifically, I am interested in the development and application of breast and cervical cancer simulation models to cancer prevention and control. My work is motivated by the fundamental concern for improving both methodology and the information available for decision making at both individual and population levels. My current research agenda includes 1) quantifying outcomes of interest such as the risk of a false positive test result or the reduction in cancer mortality under alternative screening strategies to inform individuals about trade-offs in benefits and risks from participation in those strategies; and 2) evaluation of breast cancer screening policies in the U.S. to guide policy decisions and resource allocation.

Publications

Powered by Harvard Catalyst
  • Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, Trentham-Dietz A, Munoz D, Lee SJ, Berry DA, van Ravesteyn NT, Alagoz O, Kerlikowske K, Tosteson AN, Near AM, Hoeffken A, Chang Y, Heijnsdijk EA, Chisholm G, Huang X, Huang H, Ergun MA, Gangnon R, Sprague BL, Plevritis S, Feuer E, de Koning HJ, Cronin KA. Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies. Ann Intern Med 2016; 164:215-25. PubMed
  • Haas JS, Hill DA, Wellman RD, Hubbard RA, Lee CI, Wernli KJ, Stout NK, Tosteson AN, Henderson LM, Alford-Teaster JA, Onega TL. Disparities in the use of screening magnetic resonance imaging of the breast in community practice by race, ethnicity, and socioeconomic status. Cancer 2016; 122:611-7. PubMed
  • Kim JJ, Tosteson AN, Zauber AG, Sprague BL, Stout NK, Alagoz O, Trentham-Dietz A, Armstrong K, Pruitt SL, Rutter CM, . Cancer Models and Real-world Data: Better Together. Journal of the National Cancer Institute 2015. PubMed
  • Mittmann NM, Stout NK, Lee P, Tosteson AN, Trentham-Dietz A, Alagoz O, Yaffe MJ. Total cost-effectiveness of mammography screening strategies. Health Rep 2015; 26:16-25. PubMed
  • Yaffe MJ, Mittmann N, Lee P, Tosteson AN, Trentham-Dietz A, Alagoz O, Stout NK. Modelling mammography screening for breast cancer in the Canadian context: Modification and testing of a microsimulation model. Health Rep 2015; 26:3-8. PubMed
  • Yaffe MJ, Mittmann N, Lee P, Tosteson AN, Trentham-Dietz A, Alagoz O, Stout NK. Clinical outcomes of modelling mammography screening strategies. Health Rep 2015; 26:9-15. PubMed
  • Ozanne EM, Schneider KH, Soeteman D, Stout N, Schrag D, Fordis M, Punglia RS. onlineDeCISion.org: a web-based decision aid for DCIS treatment. Breast Cancer Res Treat 2015. PubMed
  • Cevik M, Ergun MA, Stout NK, Trentham-Dietz A, Craven M, Alagoz O. Using Active Learning for Speeding up Calibration in Simulation Models. Med Decis Making 2015. PubMed
  • Weinmann S, Williams AE, Kamineni A, Buist DS, Masterson EE, Stout NK, Stark A, Ross TR, Owens CL, Field TS, Doubeni CA. Cervical cancer screening and follow-up in 4 geographically diverse US health care systems, 1998 through 2007. Cancer 2015. PubMed
  • van Ravesteyn NT, Stout NK, Schechter CB, Heijnsdijk EA, Alagoz O, Trentham-Dietz A, Mandelblatt JS, de Koning HJ. Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis. Journal of the National Cancer Institute 2015. PubMed
  • Gangnon RE, Sprague BL, Stout NK, Alagoz O, Weedon-Fekj√¶r H, Holford TR, Trentham-Dietz A. The contribution of mammography screening to breast cancer incidence trends in the United States: an updated age-period-cohort model. Cancer Epidemiol Biomarkers Prev 2015. PubMed
  • Lee CI, Cevik M, Alagoz O, Sprague BL, Tosteson AN, Miglioretti DL, Kerlikowske K, Stout NK, Jarvik JG, Ramsey SD, Lehman CD. Comparative effectiveness of combined digital mammography and tomosynthesis screening for women with dense breasts. Radiology 2015; 274:772-80. PubMed
  • Sprague BL, Stout NK, Schechter C, van Ravesteyn NT, Cevik M, Alagoz O, Lee CI, van den Broek JJ, Miglioretti DL, Mandelblatt JS, de Koning HJ, Kerlikowske K, Lehman CD, Tosteson AN. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. Ann Intern Med 2015; 162:157-66. PubMed
  • Wu AC, Gay C, Rett MD, Stout N, Weiss ST, Fuhlbrigge AL. Pharmacogenomic test that predicts response to inhaled corticosteroids in adults with asthma likely to be cost-saving. Pharmacogenomics 2015; 16:591-600. PubMed
  • Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, Berry DA, Burnside ES, Chang Y, Chisholm G, de Koning HJ, Ali Ergun M, Heijnsdijk EA, Huang H, Stout NK, Sprague BL, Trentham-Dietz A, Mandelblatt JS, Plevritis SK. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. Journal of the National Cancer Institute 2014. PubMed
  • Stout NK, Lee SJ, Schechter CB, Kerlikowske K, Alagoz O, Berry D, Buist DS, Cevik M, Chisholm G, de Koning HJ, Huang H, Hubbard RA, Miglioretti DL, Munsell MF, Trentham-Dietz A, van Ravesteyn NT, Tosteson AN, Mandelblatt JS. Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. Journal of the National Cancer Institute 2014; 106:dju092. PubMed
  • Fabian MP, Adamkiewicz G, Stout NK, Sandel M, Levy JI. A simulation model of building intervention impacts on indoor environmental quality, pediatric asthma, and costs. J Allergy Clin Immunol 2013; 133:77-84. PubMed
  • Wang AT, Fan J, Van Houten HK, Tilburt JC, Stout NK, Montori VM, Shah ND. Impact of the 2009 US Preventive Services Task Force guidelines on screening mammography rates on women in their 40s. PLoS ONE 2014; 9:e91399. PubMed
  • Stout NK, Nekhlyudov L, Li L, Malin ES, Ross-Degnan D, Buist DS, Rosenberg MA, Alfisher M, Fletcher SW. Rapid increase in breast magnetic resonance imaging use: trends from 2000 to 2011. JAMA Intern Med 2014; 174:114-21. PubMed
  • Soeteman DI, Stout NK, Ozanne EM, Greenberg C, Hassett MJ, Schrag D, Punglia RS. Modeling the effectiveness of initial management strategies for ductal carcinoma in situ. Journal of the National Cancer Institute 2013; 105:774-81. PubMed
  • Chubak J, Rutter CM, Kamineni A, Johnson EA, Stout NK, Weiss NS, Doria-Rose VP, Doubeni CA, Buist DS. Measurement in comparative effectiveness research. Am J Prev Med 2013; 44:513-9. PubMed
  • Yeh JM, Hur C, Schrag D, Kuntz KM, Ezzati M, Stout N, Ward Z, Goldie SJ. Contribution of H. pylori and smoking trends to US incidence of intestinal-type noncardia gastric adenocarcinoma: a microsimulation model. PLoS Med. 2013; 10:e1001451. PubMed
  • Stout NK, Nekhlyudov L. Early uptake of breast magnetic resonance imaging in a community-based medical practice, 2000-2004. J Womens Health (Larchmt) 2011. PubMed
  • Goldhaber-Fiebert JD, Stout NK, Goldie SJ. Empirically Evaluating Decision-Analytic Models. Value Health 2010; 13:667-74. PubMed
  • Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, Huang H, Lee SJ, Munsell M, Plevritis SK, Ravdin P, Schechter CB, Sigal B, Stoto MA, Stout NK, van Ravesteyn NT, Venier J, Zelen M, Feuer EJ, . Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med 2009; 151:738-47. PubMed
  • Stout NK,Goldie SJ. Keeping the noise down: common random numbers for disease simulation modeling. Health Care Manag Sci 2008; 11:399-406. PubMed
  • Stout NK,Goldhaber-Fiebert JD,Ortendahl JD,Goldie SJ. Trade-offs in cervical cancer prevention: balancing benefits and risks. Arch Intern Med 2008; 168:1881-9. PubMed
  • Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. Journal of the National Cancer Institute 2008; 100:308-20. PubMed
  • Tosteson AN,Stout NK,Fryback DG,Acharyya S,Herman BA,Hannah LG,Pisano ED. Cost-effectiveness of digital mammography breast cancer screening. Ann Intern Med 2008; 148:1-10. PubMed
  • Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, Goldie SJ. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007; 166:137-50. PubMed
  • Goldhaber-Fiebert JD, Stout NK, Ortendahl J, Kuntz KM, Goldie SJ, Salomon JA. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr 2007; 5:11. PubMed
  • Stout NK,Rosenberg MA,Trentham-Dietz A,Smith MA,Robinson SM,Fryback DG. Retrospective cost-effectiveness analysis of screening mammography. Journal of the National Cancer Institute 2006; 98:774-82. PubMed
  • Fryback DG,Stout NK,Rosenberg MA,Trentham-Dietz A,Kuruchittham V,Remington PL. The Wisconsin Breast Cancer Epidemiology Simulation Model. J Natl Cancer Inst Monogr 2006. PubMed
Hide